Quantum BioPharma Ltd. QNTM
At closeNov 4, 2026, 9:09 AM EST
Pre-market · Nov 4, 9:09 AM ET
Day range unavailable
- YTD
- -69.73%
- 1 year
- -78.99%
- Market cap
- 14.21M
- EPS (ttm)
- -4.98
- Shares out
- 1.92M
- Forward P/E
- -0.41
- YTD return
- -69.73%
- 1-year return
- -78.99%
- Avg volume
- 208.81K
- Previous close
- 2.21
- 52-week range
- 2.07 – 12.42
2Y -2.41 (-52.16%)
Key statistics
- Enterprise value
- -4.42M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.18
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -9.24M
- Total cash
- 6.61M
- Total debt
- 373.02K
- Return on equity
- -73.84%
- Short % of float
- 0.33%
- 50-day average
- 4.92
- 200-day average
- 14.62
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 11, 2024 | Sep 1, 2024 | -2.78 | -4.37 | -1.59 | -57.19% |
About Quantum BioPharma Ltd.
Quantum BioPharma Ltd., a biopharmaceutical company, researches and develops a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company operates through two segments, Biopharmaceutical and Strategic Investments. Its lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company is also developing a treatment for alcohol misuse for application in hospitals and other medical practices. In addition, it maintains a portfolio of strategic investments comprising loans secured by residential property. The company was formerly known as FSD Pharma Inc. and changed its name to Quantum BioPharma Ltd., in August 2024. Quantum BioPharma Ltd., is headquartered in Toronto, Canada.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- Canada
- Website
- quantumbiopharma.com
News
Top Wall Street Forecasters Revamp Thermo Fisher Scientific Expectations Ahead Of Q3 Earnings 
EXCLUSIVE: Thermo Fisher To Support Quantum Biopharma in Progressive Multiple Sclerosis Drug Trial 
Quantum BioPharma’s Licensee Unbuzzd Wellness Announces Appointment Of Michael Zapolin As CEO 
Reported Earlier, Quantum BioPharma Plans To Leave Canadian Exchange While Keeping Nasdaq Listing 
12 Health Care Stocks Moving In Monday's After-Market Session 
Rodman & Renshaw Initiates Coverage On Quantum BioPharma with Buy Rating, Announces Price Target of $8 
12 Health Care Stocks Moving In Monday's Pre-Market Session 
EXCLUSIVE: Quantum BioPharma Achieves Major Milestone With FDA Clearance for Multiple Sclerosis Trial 
12 Health Care Stocks Moving In Tuesday's Pre-Market Session 
12 Health Care Stocks Moving In Monday's After-Market Session
Your note
Sign in to keep a note on QNTM — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| AdvisorShares Investments, LLC | 1.37% | 26,233 | 84.21K | Sep 29, 2024 |
| Virtu Financial LLC | 0.60% | 11,428 | 36.68K | Sep 29, 2024 |
| HRT Financial LP | 0.52% | 10,041 | 32.23K | Sep 29, 2024 |
| Royal Bank of Canada | 0.01% | 107 | 343 | Sep 29, 2024 |
| Group One Trading, L.P. | 0.01% | 172 | 552 | Sep 29, 2024 |
| National Bank of Canada/FI | 0.00% | 48 | 154 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| AdvisorShares Trust-AdvisorShares Psychedelics ETF | 3.69% | 70,898 | 227.58K | Oct 30, 2024 |